Fintel reports that on August 22, 2023, Cantor Fitzgerald reiterated coverage of Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight recommendation.
Analyst Price Forecast Suggests 48.21% Upside
As of August 2, 2023, the average one-year price target for Jazz Pharmaceuticals is 205.40. The forecasts range from a low of 141.40 to a high of $252.00. The average price target represents an increase of 48.21% from its latest reported closing price of 138.59.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Jazz Pharmaceuticals is 3,843MM, an increase of 2.13%. The projected annual non-GAAP EPS is 18.57.
What is the Fund Sentiment?
There are 1052 funds or institutions reporting positions in Jazz Pharmaceuticals. This is a decrease of 18 owner(s) or 1.68% in the last quarter. Average portfolio weight of all funds dedicated to JAZZ is 0.30%, a decrease of 11.08%. Total shares owned by institutions decreased in the last three months by 1.00% to 66,912K shares. 
The put/call ratio of JAZZ is 0.44, indicating a bullish outlook.
What are Other Shareholders Doing?
Lsv Asset Management holds 2,317K shares representing 3.67% ownership of the company. In it's prior filing, the firm reported owning 2,318K shares, representing a decrease of 0.08%. The firm decreased its portfolio allocation in JAZZ by 16.78% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 1,943K shares representing 3.08% ownership of the company. In it's prior filing, the firm reported owning 1,944K shares, representing a decrease of 0.10%. The firm decreased its portfolio allocation in JAZZ by 12.18% over the last quarter.
Wellington Management Group Llp holds 1,868K shares representing 2.96% ownership of the company. In it's prior filing, the firm reported owning 1,856K shares, representing an increase of 0.62%. The firm decreased its portfolio allocation in JAZZ by 88.52% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,852K shares representing 2.93% ownership of the company. In it's prior filing, the firm reported owning 1,819K shares, representing an increase of 1.79%. The firm decreased its portfolio allocation in JAZZ by 13.64% over the last quarter.
Jpmorgan Chase holds 1,697K shares representing 2.69% ownership of the company. In it's prior filing, the firm reported owning 2,128K shares, representing a decrease of 25.40%. The firm increased its portfolio allocation in JAZZ by 379.95% over the last quarter.
Jazz Pharmaceuticals Background Information
(This description is provided by the company.)
Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.
Additional reading:
- Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance – Strong execution delivered second quarter 2023 total revenues of $957 million – – Commercial excellence drove continued adoption of lo
- LIBOR SUCCESSOR RATE CONFORMING CHANGES AMENDMENT
- JAZZ PHARMACEUTICALS PLC AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
